By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 191.06 |
| Change Today | $ 1.88 |
| % Change | 0.99 % |
| 52 Week High | $201.18 |
| 52 Week Low | $118.84 |
| Volume | 879,198 |
| Shares Issued | 146.80m |
| Market Cap | $28,048m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 15:59 | 127 @ $191.04 |
| 15:59 | 100 @ $191.15 |
| 15:59 | 113 @ $191.20 |
| 15:59 | 104 @ $191.08 |
| 15:59 | 100 @ $191.10 |
You are here: research